iTeos Therapeutics is a publicly-held (NASDAQ: ITOS), clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies.
Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (UCLouvain) in 2011.
In March 2020, the Company completed a $125 million Series B2 financing, and in July 2020, we completed our IPO raising over $200million of proceeds.
This additional capital will allow us to continue to develop our clinical pipeline and maintain our investments in our discovery research team to leverage its fantastic science to improve the lives of cancer patients
The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways. EOS-850 or inupadenant is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. Inupadenant is being investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors.
The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, also designed to engage the Fc gamma receptor (FcγR). An open-label Phase 1/2a clinical trial of EOS-448 is currently ongoing in adult patients with advanced solid tumors.
For more information, please visit .
iTeos Therapeutics has the ambition to become a world-class actor in the sector. Recently a senior opportunity Sr. TM Project Lead - Immuno-Oncology has opened up in the Translational Medicine (TM) department. This is a unique opportunity to lead the translational efforts for one of our leading assets in the IO space. .
Within its TM Department, iTeos is seeking a highly motivated and creative scientist with expertise in immuno-oncology or immunology research to take a leading role in defining and coordinating all TM activities related to a clinical-stage program. As the TM expert in the project team, the selected candidate will work in close interaction with other TM scientists and other departments to support the discovery of biomarkers for pharmacodynamic analysis and patient selection on multiple clinical trials, as well as to define the clinical strategy. In particular, the selected candidate will play a key role in directing and contributing to the development and outsourcing of clinically applicable biomarker assays and the analysis and reporting of the data. Moreover, in close interaction with the clinical team and other TM scientists, the successful candidate will oversee translational activities to build a scientific rationale to support the clinical strategy.
More specifically, the successful candidate will be responsible for :
Please send your CV together with an adapted cover letter to the following address : email@example.com. Please, mention the reference AD-TM in the mail object. Your application and related information will remain strictly confidential.
For our recruitments in Belgium, we closely collaborate with a Recruitment & Selection company, PaHRtners. Your application will be automatically forwarded to them. We, together with PaHRtners, will keep all your data confidential (GDPR compliant approach).